Lipoprotein(a) interactions with lipid and non-lipid risk factors in patients with early onset coronary artery disease results from the NHLBI family heart study

Atherosclerosis

Volumn 141, Issue 2, 1998, Pages 333-345

  Hopkins, Paul N ^a   Hunt, Steven C ^a   Schreiner, Pamela J ^b   Eckfeldt, John H ^c   Borecki, Ingrid B ^d   Ellison, Curtis R ^e   Williams, Roger R ^a   Siegmund, Kimberly D ^d  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e University Hospital   (United States)

Author keywords

Case control studies; Coronary heart disease; Genetics; Lipoprotein(a); Plasma cholesterol; Risk factors

Indexed keywords

LIPOPROTEIN A;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; COVALENT BOND; DISULFIDE BOND; FEMALE; GENETIC RISK; HIGH RISK POPULATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN LIPID INTERACTION; RISK FACTOR;

ADULT; AGE OF ONSET; AGED; CHOLESTEROL; CHOLESTEROL, HDL; CORONARY DISEASE; FEMALE; HUMANS; LIPIDS; LIPOPROTEIN(A); LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS;

EID: 0032401554     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00174-9     Document Type: Article

References (101)

1. Genest JJ, Martin-Munley SS, McNamara JR et al. Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation. 85:1992;2025-2033.
2. Genest JJ, McNamara JR, Ordovas JM et al. Lipoprotein cholesterol, apolipoproteins A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J Am Coll Cardiol. 19:1992;792-802.
3. Sandholzer C, Boerwinkle E, Saha N, Tong MC, Utermann G Apolipoprotein (a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease. J Clin Invest. 89:1992;1040-1046.
4. Labeur C, De Bacquer D, De Backer G et al. Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin Chem. 38:1992;2261-2266.
5. Schreiner PJ, Morrisett JD, Sharrett AR et al. Lipoprotein(a) as a risk factor for preclinical atherosclerosis. Arterioscler Thromb. 13:1993;826-833.
6. Solymoss BC, Marcil M, Wesolowska E, Gilfix BM, Lesperance J, Campeau L Relation of coronary artery disease in women <60 years of age to the combined elevation of serum lipoprotein (a) and total cholesterol to high-density cholesterol ratio. Am J Cardiol. 72:1993;1215-1219.
7. Wu JH, Kao JT, Wen MS, Wu D Coronary artery disease risk predicted by plasma concentrations of high density lipoprotein cholesterol, apolipoprotein AI, apolipoprotein B, and lipoprotein(a) in a general Chinese population. Clin Chem. 39:1993;209-212.
8. Kark JD, Sandholzer C, Friedlander Y, Utermann G Plasma Lp(a), apolipoprotein(a) isoforms and acute myocardial infarction in men and women: a case-control study in the Jerusalem population. Atherosclerosis. 98:1993;139-151.
9. Salomaa V, Rasi V, Pekkanen J et al. Haemostatic factors and prevalent coronary heart disease; the FINRISK Haemostasis Study. Eur Heart J. 15:1994;1293-1299.
10. Parlavecchia M, Pancaldi A, Taramelli R et al. Evidence that apolipoprotein(a) phenotype is a risk factor for coronary artery disease in men <55 years of age. Am J Cardiol. 74:1994;346-351.
11. Farrer M, Game FL, Albers CJ et al. Coronary artery disease is associated with increased lipoprotein (a) concentrations independent of the size of circulating apolipoprotein (a) isoforms. Arterioscler Thromb. 14:1994;1272-1283.
12. Ruiz J, Thillet J, Huby T et al. Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia. 37:1994;585-591.
13. Docci D, Manzoni G, Bilancioni R et al. Serum lipoprotein(a) and coronary artery disease in uremic patients on chronic hemodialysis. Int J Artif Organs. 17:1994;41-45.
14. Cooke T, Sheahan R, Foley D et al. Lipoprotein(a) in restenosis after percutaneous transluminal coronary angioplasty and coronary artery disease. Circulation. 89:1994;1593-1598.
15. Budde T, Fechtrup C, Bosenberg E et al. Plasma Lp(a) levels correlate with number, severity, and length extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb. 14:1994;1730-1736.
16. Kario K, Matsuo T, Imiya M et al. Close relation between lipoprotein(a) levels and atherothrombotic disease in Japanese subjects >75 years of age. Am J Cardiol. 73:1994;1187-1190.
17. Bolibar I, Thompson SG, von Eckardstein A, Sandkamp M, Assmann G Dose response relationships of serum lipid measurements with the extent of coronary stenosis. Strong, independent, and comprehensive. ECAT Angina Pectoris Study Group. Arterioscler Thromb Vasc Biol. 15:1995;1035-1042.
18. Eritsland J, Arnesen H, Berg K, Seljeflot I, Abdelnoor M Serum Lp(a) lipoprotein levels in patients with coronary artery disease and the influence of long term n 3 fatty acid supplementation. Scand J Clin Lab Invest. 55:1995;295-300.
19. Koh KK, Lee KH, Cho SK, Kim SS, Kim JJ, Lee YH Association of lipoprotein levels with atherosclerotic changes in patients with coronary artery spasm and insignificant coronary artery stenosis. Coron Artery Dis. 6:1995;235-239.
20. Maranhão RC, Vinagre CG, Arie S et al. Lipoprotein (a) in subjects with or without coronary artery disease: relation to clinical history and risk factors. Braz J Med Biol Res. 28:1995;439-446.
21. Orem A, Deger O, Kulan K, Onder E, Kiran E, Uzunosmanoglu D Evaluation of lipoprotein (a) as a risk factor for coronary artery disease in the Turkish population. Clin Biochem. 28:1995;171-173.
22. Halbmayer WM, Haushofer A, Radek J, Schon R, Deutsch M, Fischer M Platelet size, fibrinogen and lipoprotein(a) in coronary heart disease. Coron Artery Dis. 6:1995;397-402.
23. Stiel GM, Reblin T, Buhrlen M, Lattermann A, Nienaber CA Differences in lipoprotein (a) and apolipoprotein (a) levels in men and women with advanced coronary atherosclerosis. Coron Artery Dis. 6:1995;347-350.
24. Kraft HG, Lingenhel A, Köchl S et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol. 16:1996;713-719.
25. Bartens W, Nauck M, Schollmeyer P, Wanner C Elevated lipoprotein(a) and fibrinogen serum levels increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 16:1996;27-33.
26. Sunayama S, Daida H, Mokuno H et al. Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women ≥55 years of age. Circulation. 94:1996;1263-1268.
27. Orth-Gomér K, Mittleman MA, Schenck-Gustafsson K et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation. 95:1997;329-334.
28. Rosengren A, Wilhelmsen L, Eriksson E, Risberg B, Wedel H Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J. 301:1990;1248-1251.
29. Sigurdsson G, Baldursdottir A, Sigvaldason H, Agnarsson U, Thorgeirsson G, Sigfusson N Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol. 69:1992;1251-1254.
30. Cressman MD, Heyka RJ, Paganini EP, O'Neil J, Skibinski CI, Hoff HF Lipoprotein (a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 86:1992;475-482.
31. Bostom AG, Gagnon DR, Cupples LA et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation. 90:1994;1688-1695.
32. Wang XL, Tam C, McCredie RM, Wilcken DEL Determinants of severity of coronary artery disease in Australian men and women. Circulation. 89:1994;1974-1981.
33. Wald NJ, Law M, Watt HC et al. Apolipoproteins and ischaemic heart disease: implications for screening. Lancet. 343:1994;75-79.
34. Schaefer EJ, Lamon-Fava S, Jenner JL et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention trial. J Am Med Assoc. 271:1994;999-1003.
35. Cantin B, Moorjani S, Despres JP, Dagenais GR, Lupien PJ. Lp(a) ischemic heart disease. The Quebec Cardiovascular Study. J Am Coll Cardiol 1994; February Suppl: 482A.
36. Cremer P, Nagel D, Labrot B et al. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Gottingen Risk Incidence and Prevalence Study (GRIPS). Eur J Clin Invest. 24:1994;444-453.
37. Bostom AG, Cupples LA, Jenner JL et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. J Am Med Assoc. 276:1996;544-548.
38. Assmann G, Schulte H, von Eckardstein A Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol. 77:1996;1179-1184.
39. Nguyen TT, Ellefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation. 96:1997;1390-1397.
40. Wild SH, Fortmann SP, Marcovina SM A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol. 17:1997;239-245.
41. Jauhiainen M, Koskinen P, Ehnholm C et al. Lipoprotein(a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. Atherosclerosis. 89:1991;59-67.
42. Ridker PM, Hennekens CH, Stampfer MJ A prospective study of lipoprotein(a) and the risk of myocardial infarction. J Am Med Assoc. 270:1993;2195-2199.
43. Alfthan G, Pekkanen J, Jauhainen M et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 106:1994;9-19.
44. Seed M, Hoppichler F, Reaveley D et al. Relation of serum lipoprotein (a) concentration and apolipoprotein (a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. New Engl J Med. 322:1990;1494-1499.
45. Maher VMG, Kitano Y, Neuwirth C, Kehely A, Thompson GR Lp(a) and coronary atherosclerosis in familial hypercholesterolaemia. Arterioscler Thromb. 11:1991;1520.
46. Maher VMG, Brown BG, Marcovina SM, Hillger LA, Zhao X-Q, Albers JJ Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). J Am Med Assoc. 274:1995;1771-1774.
47. Maher MG, Brown BG Lipoprotein (a) and coronary heart disease. Curr Opin Lipidol. 6:1995;229-235.
48. Armstrong VW, Cremer P, Eberle E et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis. 62:1986;249-257.
49. Cambillau M, Simon A, Amar J et al. Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. The PCVMETRA Group. Arterioscler Thromb. 12:1992;1346-1352.
50. Hopkins PN, Wu LL, Hunt SC, James BC, Vincent GM, Williams RR Lipoprotein(a) interactions with lipid and non-lipid risk factors in early familial coronary artery disease. Arterioscler Thromb Vasc Biol. 17:1997;2783-2792.
51. Higgins M, Province M, Heiss G et al. NHLBI Family Heart Study: objectives and design. Am J Epidemiol. 143:1996;1219-1228.
52. Hunt SC, Williams RR, Barlow GK A comparison of positive family history definitions for defining risk of future disease. J Chron Dis. 39:1986;809-821.
53. Ledue TB, Neveux LM, Palomaki GE, Ritchie RF, Craig WY The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response. Clin Chim Acta. 223:1993;73-82.
54. Slunga L, Johnson O, Dahlen GH, Eriksson S Lipoprotein(a) and acute phase proteins in acute myocardial infarction. Scand J Clin Lab Invest. 52:1992;95-101.
55. Maeda S, Abe A, Seishima M, Makino K, Noma A, Kawade M Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis. 78:1989;145-150.
56. 2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem. 28:1982;1379-1388.
57. Friedewald WT, Levy RI, Fredrickson DS Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18:1972;499-502.
58. Utermann G Lipoprotein(a). Scriver CR, Beaudet AL, Sly WS, Valle D The metabolic and molecular basis of inherited disease. 2:1995;1887-1912 McGraw Hill, New York.
59. Clauss A Gerinnungsphysiologische schnellmethode zur bestimmung des Fibrinogens. Acta Haematol. 17:1957;237-246.
60. Declerck PJ, Alessi MC, Verstreken M, Kruithof EK, Juhan-Vague I, Collen D Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 71:1988;220-225.
61. Garg UC, Zheng ZJ, Folsom AR et al. Short term and long term variability of plasma homocysteine measurement. Clin Chem. 43:1997;141-145.
62. Dahlén G, Weinehall L, Stenlund H et al. Lp(a) and cholesterol act synergistically and predict primary myocardial infarction in Swedish males [abstract]. Atherosclerosis. 134:1997;138.
63. Barbir M, Kushwaha S, Hunt B et al. Lipoprotein (a) and accelerated coronary artery disease in cardiac transplant recipients. Lancet. 340:1992;1500-1502.
64. Schreiner PJ, Heiss G, Tyroler HA, Morrisett JD, Davis CE, Smith R Race and gender differences in the association of Lp(a) with carotid artery wall thickness. The Atherosclerosis Risk in Communities (ARIC) Study. Arteriolscler Thromb Vasc Biol. 16:1996;471-478.
65. Marcovina SM, Koschinsky ML Lipoprotein(a): structure, measurement, and clinical significance. Rifai N, Warnick GR, Dominiczak MH Handbook of lipoprotein testing. 1997;283-313 AACC Press, Washington, DC.
66. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 41:1995;246-255.
67. Usher DC, Swanson C, Rader DJ, Krämer J, Brewer HB A comparison of Lp(a) levels in fresh and frozen plasma using ELISAs with either anti-apo(a) or antio-apoB reporting antibodies. Chem Phys Lipids. 67/68:1994;243-248.
68. Loscalzo J, Weinfeld M, Fless GM, Scanu AM Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis. 10:1990;240-245.
69. Rouy D, Grailhe P, Nigon F, Chapman J, Angles-Cano E Lipoprotein (a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb. 11:1991;629-638.
70. Palabrica TM, Liu AC, Aronovitz MJ, Furie B, Lawn RM, Furie BC. Antifibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. Nature Med 1995;1:256-9.
71. Biemond BJ, Friederich PW, Koschinsky ML et al. Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo. Circulation. 96:1997;1612-1615.
72. Bihari-Varga M, Gruber E, Rotheneder M, Zechner R, Kostner GM Interaction of lipoprotein Lp(a) and low density lipoprotein with glycosaminoglycans from human aorta. Arteriosclerosis. 8:1988;851-857.
73. Argraves KM, Kozarsky KF, Fallon JT, Harpel PC, Strickland DK The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J Clin Invest. 100:1997;2170-2181.
74. Syrovets T, Thillet J, Chapman MJ, Simmet T Lipoprotein(a) is a potent chemoattractant selective for human peripheral monocytes [abstract]. Atherosclerosis. 134:1997;151.
75. Poon M, Zhang X, Dunsky KG, Taubman MB, Harpel PC Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation. 96:1997;2514-2519.
76. Kojima S, Harpel PC, Rifkin DB Lipoprotein(a) inhibits the generation of transforming growth factor β: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol. 113:1991;1439-1445.
77. Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC Activation of transforming growth factor-β is inhibited in apolipoprotein(a) transgenic mice. Nature. 370:1994;460-462.
78. Grainger DJ, Kemp PR, Metcalfe JC et al. The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med. 1:1995;74-79.
79. Sato Y, Kobori S, Sakai M et al. Lipoprotein(a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor beta activation. Atherosclerosis. 125:1996;15-26.
80. McCaffrey TA, Du B, Consigli S et al. Genomic instability in the type II TGF-β1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest. 100:1997;2182-2188.
81. Bottalico LA, Keesler GA, Fless GM, Tabas I Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and, apoprotein(a) internalization and degradation. J Biol Chem. 268:1993;8569-8573.
82. Nordestgaard BG, Nielsen LB, Juul K Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media: in vivo evidence that lipoprotein(a) may contribute to foam cell formation [abstract]. Atherosclerosis. 134:1997;145.
83. Sattler W, Kostner GM, Waeg G, Esterbauer H Oxidation of lipoprotein Lp(a). A comparison with low density lipoproteins. Biochim Biophys Acta. 1081:1991;65-74.
84. Haberland MD, Fless GM, Scanu AM, Fogelman AM Malondialdehyde modification of lipoprotein(a) produces avid uptake by human monocyte-macrophages. J Biol Chem. 267:1992;4143-4151.
85. Watts GF, Jackson P, Mandalia S et al. Nutrient intake and progression of coronary artery disease. Am J Cardiol. 73:1994;328-332.
86. Tamura A, Watanabe T, Mikuriya Y, Nasu M Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction. Br Heart J. 74:1995;365-369.
87. Terres W, Tatsis E, Pfalzer B, Beil FU, Beisiegel U, Hamm CW Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a). Circulation. 91:1995;948-950.
88. Moliterno DJ, Lange RA, Meidell RS et al. Relation of plasma lipoprotein(a) to infarct artery patency in survivors of myocardial infarction. Circulation. 88:1993;935-940.
89. Koltringer P, Langsteger W, Lind P, Reisecker F, Eber O, Jurgens G Increased mortality in patients with elevated serum levels of lipoprotein(a). Arterioscler Thromb. 11:1991;1518.
90. Michishita I, Shibazaki Y, Umeda K, Mizuno K, Watanabe S, Genda A Serum lipoprotein (a) as a restenosis risk factor after percutaneous transluminal coronary angioplasty [abstract]. Arteriosclerosis. 11:1991;1423.
91. Hearn JA, Donohue BC, Ba'albaki H et al. Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol. 69:1992;736-739.
92. Tenda K, Saikawa T, Maeda T et al. The relationship between serum lipoprotein(a) and restenosis after initial elective percutaneous transluminal coronary angioplasty. Jap Circ J. 57:1993;789-795.
93. Daida H, Lee YJ, Yokoi H et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low-density lipoprotein apheresis. Am J Cardiol. 73:1994;1037-1040.
94. Yamaguchi H, Lee YJ, Daida H et al. Effectiveness of LDL apheresis in preventing restenosis after percutaneous transluminal coronary angioplasty (PTCA): LDL apheresis angioplasty restenosis trial (L ART). Chem Phys Lipids. 68:1994;399-403.
95. Yamamoto H, Imazu M, Yamabe T, Ueda H, Hattori Y, Yamakido M Risk factors for restenosis after percutaneous transluminal coronary angioplasty: role of lipoprotein (a). Am Heart J. 130:1995;1168-1173.
96. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 91:1995;1403-1409.
97. Horie H, Takahashi M, Izumi M et al. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty. Circulation. 96:1997;166-173.
98. Kronenberg F, Lobentanz EM, Konig P, Utermann G, Dieplinger H Effect of sample storage on the measurement of lipoprotein [a], apolipoproteins B and A-IV, total and high density lipoprotein cholesterol and triglycerides. J Lipid Res. 35:1994;1318-1328.
99. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol. 16:1996;1568-1572.
100. Lovejoy K, Bachorik PS Lp(a) measurements may be unreliable in stored sera. Circulation. 90 (Suppl I):1994;504.
101. Ridker PM, Stampfer MJ, Hennekens CH Plasma concentration of lipoprotein(a) and the risk of future stroke. J Am Med Assoc. 273:1995;1269-1273.